The potential for dropped tablets will take center stage at an Oct. 12 meeting of the US FDA's Anesthetic And Analgesic Drug Products Advisory Committee, where panelists will weigh in on a series of questions the agency has about AcelRx Pharmaceuticals Inc.'s opioid Dsuvia (sufentanil sublingual tablet).
Designed for the management of moderate-to-severe acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate, Dsuvia would be the first sublingual sufentanil product backed for the indication if
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?